Global Recombinant Human GM-CSF for Injection Market Growth 2026-2032
The global Recombinant Human GM-CSF for Injection market size is predicted to grow from US$ 95.21 million in 2025 to US$ 124 million in 2032; it is expected to grow at a CAGR of 3.9% from 2026 to 2032.
Recombinant Human GM-CSF for Injection is a biopharmaceutical product that plays a critical role in stimulating the growth and function of granulocytes and macrophages, key components of the immune system. It is used to treat various medical conditions, including neutropenia, leukemia, and as an adjunct therapy for certain cancer treatments. The market for this product is substantial, driven by the rising prevalence of diseases that compromise the immune system and the development of immunotherapies. Its future development is likely to involve expanded applications in immune-related therapies, further improving patient outcomes in the treatment of various disorders.
Recombinant Human GM-CSF for Injection is a crucial biopharmaceutical product widely used in the treatment of various diseases, particularly leukemia and malignant tumors. The market for this product is substantial and continuously expanding, driven by advancements in medical technology and therapeutic approaches. In the future, it is expected that this field will continue to evolve, with specific uses of recombinant human GM-CSF potentially extending to include the treatment of more cancer types, offering further growth opportunities in the biopharmaceutical industry.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human GM-CSF for Injection Industry Forecast” looks at past sales and reviews total world Recombinant Human GM-CSF for Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Recombinant Human GM-CSF for Injection sales for 2026 through 2032. With Recombinant Human GM-CSF for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human GM-CSF for Injection industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human GM-CSF for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human GM-CSF for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human GM-CSF for Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human GM-CSF for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human GM-CSF for Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human GM-CSF for Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Recombinant Human GM-CSF for Injection is a biopharmaceutical product that plays a critical role in stimulating the growth and function of granulocytes and macrophages, key components of the immune system. It is used to treat various medical conditions, including neutropenia, leukemia, and as an adjunct therapy for certain cancer treatments. The market for this product is substantial, driven by the rising prevalence of diseases that compromise the immune system and the development of immunotherapies. Its future development is likely to involve expanded applications in immune-related therapies, further improving patient outcomes in the treatment of various disorders.
Recombinant Human GM-CSF for Injection is a crucial biopharmaceutical product widely used in the treatment of various diseases, particularly leukemia and malignant tumors. The market for this product is substantial and continuously expanding, driven by advancements in medical technology and therapeutic approaches. In the future, it is expected that this field will continue to evolve, with specific uses of recombinant human GM-CSF potentially extending to include the treatment of more cancer types, offering further growth opportunities in the biopharmaceutical industry.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human GM-CSF for Injection Industry Forecast” looks at past sales and reviews total world Recombinant Human GM-CSF for Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Recombinant Human GM-CSF for Injection sales for 2026 through 2032. With Recombinant Human GM-CSF for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human GM-CSF for Injection industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human GM-CSF for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human GM-CSF for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human GM-CSF for Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human GM-CSF for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human GM-CSF for Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human GM-CSF for Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 75ug
- 150ug
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- Changchun GeneScience
- Hainan Unipul Pharmaceutical
- Harbin Pharmaceutical Group
- Guangzhou Baiyunshan Baidi Biotechnology
- What is the 10-year outlook for the global Recombinant Human GM-CSF for Injection market?
- What factors are driving Recombinant Human GM-CSF for Injection market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Recombinant Human GM-CSF for Injection market opportunities vary by end market size?
- How does Recombinant Human GM-CSF for Injection break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Country/Region, 2021, 2025 & 2032
2.2 Recombinant Human GM-CSF for Injection Segment by Type
2.2.1 75ug
2.2.2 150ug
2.2.3 Recombinant Human GM-CSF for Injection Sales by Type
2.2.3.1 Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
2.2.3.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Type (2021-2026)
2.3 Recombinant Human GM-CSF for Injection Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Recombinant Human GM-CSF for Injection Sales by Application
2.3.4.1 Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2021-2026)
2.3.4.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Recombinant Human GM-CSF for Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Human GM-CSF for Injection Breakdown Data by Company
3.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Company (2021-2026)
3.1.2 Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2021-2026)
3.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Recombinant Human GM-CSF for Injection Revenue by Company (2021-2026)
3.2.2 Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2021-2026)
3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Company
3.4 Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human GM-CSF for Injection Product Location Distribution
3.4.2 Players Recombinant Human GM-CSF for Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human GM-CSF for Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Recombinant Human GM-CSF for Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Recombinant Human GM-CSF for Injection Sales Growth
4.4 APAC Recombinant Human GM-CSF for Injection Sales Growth
4.5 Europe Recombinant Human GM-CSF for Injection Sales Growth
4.6 Middle East & Africa Recombinant Human GM-CSF for Injection Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human GM-CSF for Injection Sales by Country
5.1.1 Americas Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
5.1.2 Americas Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
5.2 Americas Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
5.3 Americas Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human GM-CSF for Injection Sales by Region
6.1.1 APAC Recombinant Human GM-CSF for Injection Sales by Region (2021-2026)
6.1.2 APAC Recombinant Human GM-CSF for Injection Revenue by Region (2021-2026)
6.2 APAC Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
6.3 APAC Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human GM-CSF for Injection by Country
7.1.1 Europe Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
7.1.2 Europe Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
7.2 Europe Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
7.3 Europe Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human GM-CSF for Injection by Country
8.1.1 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection
10.3 Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
10.4 Industry Chain Structure of Recombinant Human GM-CSF for Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human GM-CSF for Injection Distributors
11.3 Recombinant Human GM-CSF for Injection Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
12.1 Global Recombinant Human GM-CSF for Injection Market Size Forecast by Region
12.1.1 Global Recombinant Human GM-CSF for Injection Forecast by Region (2027-2032)
12.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Recombinant Human GM-CSF for Injection Forecast by Type (2027-2032)
12.7 Global Recombinant Human GM-CSF for Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.1.3 Sanofi Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Changchun GeneScience
13.2.1 Changchun GeneScience Company Information
13.2.2 Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.2.3 Changchun GeneScience Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Changchun GeneScience Main Business Overview
13.2.5 Changchun GeneScience Latest Developments
13.3 Hainan Unipul Pharmaceutical
13.3.1 Hainan Unipul Pharmaceutical Company Information
13.3.2 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.3.3 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Hainan Unipul Pharmaceutical Main Business Overview
13.3.5 Hainan Unipul Pharmaceutical Latest Developments
13.4 Harbin Pharmaceutical Group
13.4.1 Harbin Pharmaceutical Group Company Information
13.4.2 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.4.3 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Harbin Pharmaceutical Group Main Business Overview
13.4.5 Harbin Pharmaceutical Group Latest Developments
13.5 Guangzhou Baiyunshan Baidi Biotechnology
13.5.1 Guangzhou Baiyunshan Baidi Biotechnology Company Information
13.5.2 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.5.3 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Guangzhou Baiyunshan Baidi Biotechnology Main Business Overview
13.5.5 Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Country/Region, 2021, 2025 & 2032
2.2 Recombinant Human GM-CSF for Injection Segment by Type
2.2.1 75ug
2.2.2 150ug
2.2.3 Recombinant Human GM-CSF for Injection Sales by Type
2.2.3.1 Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
2.2.3.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Type (2021-2026)
2.3 Recombinant Human GM-CSF for Injection Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Recombinant Human GM-CSF for Injection Sales by Application
2.3.4.1 Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2021-2026)
2.3.4.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Recombinant Human GM-CSF for Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Human GM-CSF for Injection Breakdown Data by Company
3.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Company (2021-2026)
3.1.2 Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2021-2026)
3.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Recombinant Human GM-CSF for Injection Revenue by Company (2021-2026)
3.2.2 Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2021-2026)
3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Company
3.4 Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human GM-CSF for Injection Product Location Distribution
3.4.2 Players Recombinant Human GM-CSF for Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human GM-CSF for Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Recombinant Human GM-CSF for Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Recombinant Human GM-CSF for Injection Sales Growth
4.4 APAC Recombinant Human GM-CSF for Injection Sales Growth
4.5 Europe Recombinant Human GM-CSF for Injection Sales Growth
4.6 Middle East & Africa Recombinant Human GM-CSF for Injection Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human GM-CSF for Injection Sales by Country
5.1.1 Americas Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
5.1.2 Americas Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
5.2 Americas Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
5.3 Americas Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human GM-CSF for Injection Sales by Region
6.1.1 APAC Recombinant Human GM-CSF for Injection Sales by Region (2021-2026)
6.1.2 APAC Recombinant Human GM-CSF for Injection Revenue by Region (2021-2026)
6.2 APAC Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
6.3 APAC Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human GM-CSF for Injection by Country
7.1.1 Europe Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
7.1.2 Europe Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
7.2 Europe Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
7.3 Europe Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human GM-CSF for Injection by Country
8.1.1 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection
10.3 Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
10.4 Industry Chain Structure of Recombinant Human GM-CSF for Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human GM-CSF for Injection Distributors
11.3 Recombinant Human GM-CSF for Injection Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
12.1 Global Recombinant Human GM-CSF for Injection Market Size Forecast by Region
12.1.1 Global Recombinant Human GM-CSF for Injection Forecast by Region (2027-2032)
12.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Recombinant Human GM-CSF for Injection Forecast by Type (2027-2032)
12.7 Global Recombinant Human GM-CSF for Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.1.3 Sanofi Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Changchun GeneScience
13.2.1 Changchun GeneScience Company Information
13.2.2 Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.2.3 Changchun GeneScience Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Changchun GeneScience Main Business Overview
13.2.5 Changchun GeneScience Latest Developments
13.3 Hainan Unipul Pharmaceutical
13.3.1 Hainan Unipul Pharmaceutical Company Information
13.3.2 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.3.3 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Hainan Unipul Pharmaceutical Main Business Overview
13.3.5 Hainan Unipul Pharmaceutical Latest Developments
13.4 Harbin Pharmaceutical Group
13.4.1 Harbin Pharmaceutical Group Company Information
13.4.2 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.4.3 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Harbin Pharmaceutical Group Main Business Overview
13.4.5 Harbin Pharmaceutical Group Latest Developments
13.5 Guangzhou Baiyunshan Baidi Biotechnology
13.5.1 Guangzhou Baiyunshan Baidi Biotechnology Company Information
13.5.2 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.5.3 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Guangzhou Baiyunshan Baidi Biotechnology Main Business Overview
13.5.5 Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 75ug
Table 4. Major Players of 150ug
Table 5. Global Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 6. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Table 7. Global Recombinant Human GM-CSF for Injection Revenue by Type (2021-2026) & ($ million)
Table 8. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2021-2026)
Table 9. Global Recombinant Human GM-CSF for Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Recombinant Human GM-CSF for Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2021-2026)
Table 12. Global Recombinant Human GM-CSF for Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Recombinant Human GM-CSF for Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Recombinant Human GM-CSF for Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2021-2026)
Table 17. Global Recombinant Human GM-CSF for Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Recombinant Human GM-CSF for Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution and Sales Area
Table 21. Players Recombinant Human GM-CSF for Injection Products Offered
Table 22. Recombinant Human GM-CSF for Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Recombinant Human GM-CSF for Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Recombinant Human GM-CSF for Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Recombinant Human GM-CSF for Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Recombinant Human GM-CSF for Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Recombinant Human GM-CSF for Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 37. Americas Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Recombinant Human GM-CSF for Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Recombinant Human GM-CSF for Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 42. APAC Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 46. Europe Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Recombinant Human GM-CSF for Injection
Table 52. Key Market Challenges & Risks of Recombinant Human GM-CSF for Injection
Table 53. Key Industry Trends of Recombinant Human GM-CSF for Injection
Table 54. Recombinant Human GM-CSF for Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Recombinant Human GM-CSF for Injection Distributors List
Table 57. Recombinant Human GM-CSF for Injection Customer List
Table 58. Global Recombinant Human GM-CSF for Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Recombinant Human GM-CSF for Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Recombinant Human GM-CSF for Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Recombinant Human GM-CSF for Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Sanofi Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 74. Sanofi Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Sanofi Main Business
Table 76. Sanofi Latest Developments
Table 77. Changchun GeneScience Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 79. Changchun GeneScience Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Changchun GeneScience Main Business
Table 81. Changchun GeneScience Latest Developments
Table 82. Hainan Unipul Pharmaceutical Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 84. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Hainan Unipul Pharmaceutical Main Business
Table 86. Hainan Unipul Pharmaceutical Latest Developments
Table 87. Harbin Pharmaceutical Group Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 89. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Harbin Pharmaceutical Group Main Business
Table 91. Harbin Pharmaceutical Group Latest Developments
Table 92. Guangzhou Baiyunshan Baidi Biotechnology Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 94. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Guangzhou Baiyunshan Baidi Biotechnology Main Business
Table 96. Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
Table 1. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 75ug
Table 4. Major Players of 150ug
Table 5. Global Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 6. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Table 7. Global Recombinant Human GM-CSF for Injection Revenue by Type (2021-2026) & ($ million)
Table 8. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2021-2026)
Table 9. Global Recombinant Human GM-CSF for Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Recombinant Human GM-CSF for Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2021-2026)
Table 12. Global Recombinant Human GM-CSF for Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Recombinant Human GM-CSF for Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Recombinant Human GM-CSF for Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2021-2026)
Table 17. Global Recombinant Human GM-CSF for Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Recombinant Human GM-CSF for Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution and Sales Area
Table 21. Players Recombinant Human GM-CSF for Injection Products Offered
Table 22. Recombinant Human GM-CSF for Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Recombinant Human GM-CSF for Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Recombinant Human GM-CSF for Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Recombinant Human GM-CSF for Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Recombinant Human GM-CSF for Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Recombinant Human GM-CSF for Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 37. Americas Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Recombinant Human GM-CSF for Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Recombinant Human GM-CSF for Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 42. APAC Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Recombinant Human GM-CSF for Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 46. Europe Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Recombinant Human GM-CSF for Injection
Table 52. Key Market Challenges & Risks of Recombinant Human GM-CSF for Injection
Table 53. Key Industry Trends of Recombinant Human GM-CSF for Injection
Table 54. Recombinant Human GM-CSF for Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Recombinant Human GM-CSF for Injection Distributors List
Table 57. Recombinant Human GM-CSF for Injection Customer List
Table 58. Global Recombinant Human GM-CSF for Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Recombinant Human GM-CSF for Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Recombinant Human GM-CSF for Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Recombinant Human GM-CSF for Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Sanofi Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 74. Sanofi Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Sanofi Main Business
Table 76. Sanofi Latest Developments
Table 77. Changchun GeneScience Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 79. Changchun GeneScience Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Changchun GeneScience Main Business
Table 81. Changchun GeneScience Latest Developments
Table 82. Hainan Unipul Pharmaceutical Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 84. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Hainan Unipul Pharmaceutical Main Business
Table 86. Hainan Unipul Pharmaceutical Latest Developments
Table 87. Harbin Pharmaceutical Group Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 89. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Harbin Pharmaceutical Group Main Business
Table 91. Harbin Pharmaceutical Group Latest Developments
Table 92. Guangzhou Baiyunshan Baidi Biotechnology Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 94. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Guangzhou Baiyunshan Baidi Biotechnology Main Business
Table 96. Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Human GM-CSF for Injection
Figure 2. Recombinant Human GM-CSF for Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human GM-CSF for Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Recombinant Human GM-CSF for Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Recombinant Human GM-CSF for Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2025)
Figure 10. Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 75ug
Figure 12. Product Picture of 150ug
Figure 13. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type in 2026
Figure 14. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2021-2026)
Figure 15. Recombinant Human GM-CSF for Injection Consumed in Hospital
Figure 16. Global Recombinant Human GM-CSF for Injection Market: Hospital (2021-2026) & (K Units)
Figure 17. Recombinant Human GM-CSF for Injection Consumed in Clinic
Figure 18. Global Recombinant Human GM-CSF for Injection Market: Clinic (2021-2026) & (K Units)
Figure 19. Recombinant Human GM-CSF for Injection Consumed in Others
Figure 20. Global Recombinant Human GM-CSF for Injection Market: Others (2021-2026) & (K Units)
Figure 21. Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2025)
Figure 22. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application in 2026
Figure 23. Recombinant Human GM-CSF for Injection Sales by Company in 2026 (K Units)
Figure 24. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company in 2026
Figure 25. Recombinant Human GM-CSF for Injection Revenue by Company in 2026 ($ millions)
Figure 26. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company in 2026
Figure 27. Global Recombinant Human GM-CSF for Injection Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 30. Americas Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 31. APAC Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 32. APAC Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 33. Europe Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 34. Europe Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 37. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2026
Figure 38. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Figure 39. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 40. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 41. United States Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region in 2026
Figure 46. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Region (2021-2026)
Figure 47. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 48. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 49. China Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. India Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2026
Figure 57. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Figure 58. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 59. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 60. Germany Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. France Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 68. Egypt Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection in 2026
Figure 74. Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
Figure 75. Industry Chain Structure of Recombinant Human GM-CSF for Injection
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Human GM-CSF for Injection Sales Market Forecast by Region (2027-2032)
Figure 78. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Recombinant Human GM-CSF for Injection
Figure 2. Recombinant Human GM-CSF for Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human GM-CSF for Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Recombinant Human GM-CSF for Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Recombinant Human GM-CSF for Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2025)
Figure 10. Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 75ug
Figure 12. Product Picture of 150ug
Figure 13. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type in 2026
Figure 14. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2021-2026)
Figure 15. Recombinant Human GM-CSF for Injection Consumed in Hospital
Figure 16. Global Recombinant Human GM-CSF for Injection Market: Hospital (2021-2026) & (K Units)
Figure 17. Recombinant Human GM-CSF for Injection Consumed in Clinic
Figure 18. Global Recombinant Human GM-CSF for Injection Market: Clinic (2021-2026) & (K Units)
Figure 19. Recombinant Human GM-CSF for Injection Consumed in Others
Figure 20. Global Recombinant Human GM-CSF for Injection Market: Others (2021-2026) & (K Units)
Figure 21. Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2025)
Figure 22. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application in 2026
Figure 23. Recombinant Human GM-CSF for Injection Sales by Company in 2026 (K Units)
Figure 24. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company in 2026
Figure 25. Recombinant Human GM-CSF for Injection Revenue by Company in 2026 ($ millions)
Figure 26. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company in 2026
Figure 27. Global Recombinant Human GM-CSF for Injection Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 30. Americas Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 31. APAC Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 32. APAC Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 33. Europe Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 34. Europe Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Recombinant Human GM-CSF for Injection Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue 2021-2026 ($ millions)
Figure 37. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2026
Figure 38. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Figure 39. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 40. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 41. United States Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region in 2026
Figure 46. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Region (2021-2026)
Figure 47. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 48. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 49. China Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. India Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2026
Figure 57. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2021-2026)
Figure 58. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 59. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 60. Germany Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. France Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Application (2021-2026)
Figure 68. Egypt Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Recombinant Human GM-CSF for Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection in 2026
Figure 74. Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
Figure 75. Industry Chain Structure of Recombinant Human GM-CSF for Injection
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Human GM-CSF for Injection Sales Market Forecast by Region (2027-2032)
Figure 78. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Application (2027-2032)
